PB Fintech may pursue insurance manufacturing if IRDAI commission cuts are finalised
PB Fintech says proposed IRDAI commission caps could reduce revenue by about 30%, with non-life revenue potentially down 33–40%. Policybazaar’s parent may seek an insurance manufacturing licence as it prepares for the proposed reforms.
The development
PB Fintech said proposed IRDAI commission caps could erase 30% of revenue and may prompt it to seek an insurance manufacturing licence. Its non-life revenue could fall 33-40% if general insurance commissions decline around 60%, partly offset by 15–20% volume growth.
The numbers
- 30%
- 33-40%
- around 60%
- 15–20%
- five-year
Why it matters to operators and investors
Insurance distribution operators should prepare for lower commission economics and a more vertically integrated Policybazaar if IRDAI finalises the proposed caps.
What to watch next
- Final IRDAI notification, including exact commission caps, effective date, grandfathering and product-specific treatment.
- PB Fintech disclosure of a board-approved insurance-manufacturing strategy, licence application, JV, capital raise or senior insurance underwriting hires.
- Management guidance changes for insurance revenue, adjusted EBITDA, customer acquisition cost or renewal contribution.
- Insurer responses: reduced marketplace payouts, new service-fee contracts, exclusive partnerships or investment in direct channels.
- Competitive actions from other aggregators, brokers and digital insurers seeking licences or acquiring insurance stakes.
The counter-case
The headline may overstate both the immediacy and attractiveness of a pivot to insurance manufacturing. A licence would require material capital, regulatory approvals, underwriting capabilities, claims infrastructure, reserving discipline and risk-bearing capacity—none of which Policybazaar’s distribution model necessarily proves. Commission caps could compress earnings before any manufacturing operation contributes, while becoming an insurer could introduce loss-ratio volatility, solvency requirements and channel-conflict risk with existing insurer partners. The cited revenue impact is contingent on rules being finalized as proposed and may be mitigated through product mix, fees, productivity or insurer renegotiations.